Merck tops quarterly estimates, hikes profit outlook as new Keytruda form shows strength

Merck's immunotherapy Keytruda, including a newer injectable form of the drug, showed stronger-than-expected sales.

NewsBeagle is a discovery engine. We show the headline, a short source-supplied summary and clear attribution. The complete reporting remains with the publisher.